Recent genome-wide studies have reported novel associations between common
polymorphisms and susceptibility to many major infectious diseases in humans. In parallel …

During the late 1990s and early 2000s, major advances were made in the treatment of
patients with chronic hepatitis C virus (HCV) infection. Interferon, combination interferon plus …

Hepatitis C virus (HCV) is an RNA virus that affects> 180 million individuals worldwide with a
high propensity for chronic infection. Children with HCV infection differ from adults in several …

Summary Background Chronic hepatitis C (CHC) infection is a risk factor for both the
development of end‐stage liver disease and hepatocellular carcinoma (HCC). Globally …

The introduction of direct acting antiviral agents (DAAs) will markedly change treatment
options for individuals who have a chronic HCV infection. Within the next few months …

Genome-wide association studies (GWAS) of responses to drugs, including clopidogrel,
pegylated-interferon and carbamazepine, have led to the identification of specific patient …

Background Since 2009, several studies have identified single-nucleotide polymorphisms
(SNPs) near the gene encoding for interleukin (IL)-28 (IL28B) that are strongly associated …

Single nucleotide polymorphisms (SNPs) near the interleukin 28B (IL28B) region are the
strongest baseline predictors of a sustained virologic response (SVR) to peg‐interferon …

Aliment Pharmacol Ther 2011; 34: 286–296 Summary Background Hepatitis C virus (HCV)
genotype 6 is common among patients from Southeast Asia and the surrounding regions …

The early, accurate diagnosis and risk stratification of sepsis remains an important challenge
in the critically ill. Since traditional biomarker strategies have not yielded a gold standard …